A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy ≥1 Month to <4 Years of Age With Partial-onset Seizures
Latest Information Update: 13 Jan 2022
At a glance
- Drugs Lacosamide (Primary)
- Indications Epilepsy; Partial epilepsies
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors UCB; UCB Biosciences
- 12 Dec 2020 This trial has been Discontinued in Germany, according to European Clinical Trials Database record.
- 22 Jun 2020 Status changed from active, no longer recruiting to completed.
- 03 Jun 2020 This trial has been discontinued in Spain, according to European Clinical Trials Database record.